poisar

Stocks · News reference

World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

Aug 28, 2026, 4:43 PMBenzinga Newsdesk

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CODXEBSGILDGOVXINOJNJMRKMRNANNVCOSURREGNSPY
Source
benzinga
Observed
Aug 28, 2026, 4:43 PM
Checked
Aug 28, 2026, 4:43 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 28, 2026, 3:31 PMBrendan Coffey

    Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?

    The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

    Read original at the-motley-fool
    BBHPJPAMGNLLYGILD
  5. Aug 28, 2026, 11:07 AMEric Volkman

    Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

    Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

    Read original at the-motley-fool
    RVMDRVMDWLLYJNJABBV